(Q38078993)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

PARP inhibitors in cancer therapy: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Elena Casale

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alessia Montagnoli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alessandra Cirla

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

5 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Patents

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

503-514

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

The role of poly(ADP-ribose) polymerase-1 in CNS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase-2 [corrected] controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor/peroxisome proliferator-activated receptor-gamma [corrected] heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Zinc binding catalytic domain of human tankyrase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Structural basis of selective inhibition of human tankyrases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Cancer susceptibility and the functions of BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Does PTEN loss impair DNA double-strand break repair by homologous recombination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PTEN in DNA damage repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Systemic elevation of PTEN induces a tumor-suppressive metabolic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Human MRE11 is inactivated in mismatch repair-deficient cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Microsatellite instability in colorectal cancer-the stable evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Targeted therapy for brain tumours: role of PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Role of PARP inhibitors in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Targeting poly(ADP-ribose) polymerase activity for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

PARP inhibitors stumble in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.768615

10.1517/13543776.2013.768615

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23379721%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference